Tianjin Institute of Pharmaceutical Research

Tianjin Institute of Pharmaceutical Research Co., Ltd.

Lida Tang

Weiren Xu

Yuli Wang

Guilong Zhao

Meixiang Zou

Peng Liu

Wei Liu

Yuqiang Liu

Yafei Xie

Bingni Liu

Yuquan Li

Shijun Zhang

Wei Wei

Chubing Tan

Haizhi Zhang

Jingwei Wu

Changying Liu

Huihui Chen

Lei Liu

Lijun Liu

Jianping Yong

Xuyuan Liu

Hua Shao

Jiajia Hou

Jiang Wu

Wen Du

Zhuanyou Zhao

Changjiang Huang

Weiting Wang

Ying Liu

Qian Shang

Yingmei Han

Guangping Xia

Naxia Zhao

Yiliang Li

Bing Yu

Zhixing Zhou

Wulin Liu

Xiaoli Fu

Dengke Liu

Nan Yue

Chuan Li

Furong Chen

Yunsong Zhou

Yigui Zhao

Deguang Zhi

Mo Liu

Jianwu Wang

Jianping Wong

Xiaowen Ren

Lingjun Li

Jing Yuan

Hui Yan

Songhui Wang

Xuemin Zheng

Wengong Xi

Qunchao Wei

Chunhua Hao

Xiangwei Xu

The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also provides a crystalline form of the compound, a preparation method and use of the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compounds having the structure of formula (I) of the present invention are present in a solid form, which not only can solve the problem of clopidogrel resistance, but also can solve the problem of severe hemorrhagic side effect and poor safety of some drugs, as well as the problem of poor stability of existing compounds. It can be developed into an ADP receptor antagonist antiplatelet agent with clear therapeutic effect, no resistance and better stability. 

Thienopyridine derivatives containing unsaturated aliphatic olefinic bond, preparation method and use thereof

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

Crystal form of urate transporter 1 inhibitor and preparation method and use thereof

Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization. 

Method for preparing urate transporter 1 inhibitor

The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, 

Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof

The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R-Rare as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof. 

Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

Provided is a pharmaceutical composition comprising candesartan or ester thereof and chlorthalidone, and use thereof, wherein the weight ratio of candesartan or ester thereof to chlorthalidone is 5.3:1 to 1:6.25. The pharmaceutical composition has a synergistic antihypertensive effect, and can enhance the antihypertensive effect and extend duration of antihypertension.

Pharmaceutical composition comprising candesartan or ester thereof and chlortalidone, and use thereof

The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of Rand Rare selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H. 

Phenyl C-glucoside derivatives, preparation methods and uses thereof

This invention provides a method for preparing cycloastragenol monoglucoside CMG (cycloastragenol-6-O-&#x3b2;-D-glucoside), comprising the steps of: a. using astragaloside IV or Astragali extracts prepared by a conventional method as raw materials and adding an appropriate solvent thereinto to form a raw material solution; b. adding hydrolase and allowing for hydrolysis at a constant temperature to obtain a hydrolysate; c. separating the hydrolysate with macroporous adsorption resin; and d. obtaining the product by purification and separation. The present invention further provides cycloastragenol-6-O-&#x3b2;-D-glucoside prepared according to the method of this invention as well as its use in the preparation of a medicament for treating cardiovascular diseases and pharmaceutical compositions comprising the same.

Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof

A compound with the structure of the formula (I) or a pharmaceutically acceptable salt, a preparation method and use thereof are disclosed in the present invention, wherein R is cyano group. The compound provided by the present invention has an antiplatelet aggregation activity and can be used in preparing a medicament for preventing or treating cardiac and cerebral vascular diseases such as coronary artery syndromes, myocardial infarction and myocardial ischemia which are caused by platelet aggregation. 

Thienopyridine ester derivative containing cyano group, preparation method, use and composition thereof

The present invention relates to the field of drugs associated with treating diabetes. Particularly, the present invention relates to a dipeptidyl peptidase-IV inhibitor having the structure shown by formula (I), which contains amide thiazole structure and has an effect on treating diabetes, and a preparation method and a pharmaceutical composition containing it, as well as use thereof in manufacture of the drugs for treating the diabetes, wherein, Ris methyl; Ris phenyl; phenyl, 2-thienyl substituted in a mono-substituted, bi-substituted manner by fluorine and methyl.

Amide thiazole derivative, preparation method and uses thereof

The present invention relates to the field of a medicine for treating diseases associated with inflammation, immunity or infection, and in particular, to glycyrrhetinic acid-30-amide derivatives of general formula I and their preparation, and a pharmaceutical composition containing the same. Said derivatives and composition exhibit anti-inflammatory, analgesic, anti-allergic, cough-preventing, liver-protecting and anti-viral properties, wherein each group is as defined in the description.

Glycyrrhetinic acid-30-amide derivatives and their use

Growing community of inventors

Tianjin, China

Lida Tang